Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
High performance
13%, p = 0.032) 20
These cliniciansnot the platformdecide who receives medication based on individual medical evaluation
The clinical insights from these studies demonstrate how our portfolio may offer more tailored, individualised treatment options for people living with obesity. The data presented on Roches obesity assets include: Enicepatide (CT-388) : Late-breaking data from the Phase II (CT388-103) study will highlight clinical weight loss outcomes from investigational enicepatide in people living with overweight/obesity
From Dr Linsemans preclinical work in mice, Immunocal shows great promise
US$ 20.98
US$ 23.63
US$ 28.70
US$ 27.03
US$ 25.84
